Mostrando 2 resultados de: 2
Filtros aplicados
Área temáticas
Bioquímica(1)
Enfermedades(1)
Farmacología y terapéutica(1)
Fisiología y materias afines(1)
Origen
scopus(2)
Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population
ArticleAbstract: CYP2C9, CYP2C19 and CYP2D6 metabolize around 40 % of drugs and their genes vary across populations.Palabras claves:Afro-Caribbean, Amerindian, COSTA RICA, CYP2C19, CYP2C9, CYP2D6, Genomic ancestryAutores:Adrián LLerena, Alonso-Vilatela E., Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Monroy-Jaramillo N., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Vázquez T.C.Fuentes:scopusPbkp_redictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen
ReviewAbstract: Bevacizumab was the first molecular-targeted antiangiogenic therapy approved for the treatment of mePalabras claves:Bevacizumab, Biomarker, Cáncer, colorectalAutores:Adrián LLerena, Alonso I., Arroyo G., de Andrés F., Estévez-Carrizo F.E., González-Vacarezza N., Martínez J.Fuentes:scopus